Tesamorelin dosage chart by version

The first three rows describe the approved product and the studies behind it, which were run in adults with HIV and extra belly fat. The last row is what vendors describe for research vials, and it comes with no label. Compare across a row before you compare amounts, and read the source column too. Background on the peptide is on the tesamorelin page.

Research tesamorelin is sold as a freeze-dried powder, and vial sizes vary by seller. The tables below use 10 mg and 5 mg vials. You mix it with bacteriostatic water, which is sterile water with a preservative so one vial can be drawn from more than once. The approved products come as kits with their own water and are mixed to their own volumes, so the research-vial tables below don't apply to them: 0.35 mL (35 units on a U-100 syringe) is the Egrifta SV dose, and 0.16 mL (16 units) is the Egrifta WR dose.

The tables show units on a U-100 syringe, which holds 100 units in 1 mL, for 1, 2 and 3 mL of water. The amounts are 1 mg, the approved 1.4 mg and 2 mg.

Units are math from the chart amounts, with strength rounded to one decimal. "Over one syringe" means the draw is more than the 100 units a 1 mL syringe holds. More water makes each draw bigger and easier to read.

For any other vial, water or amount, the reconstitution calculator does the same math.

Once a day. Both labels give one injection a day, into the belly, rotating spots and staying away from scars, bruises and the navel.

No time of day. The labels don't set one. Pick a time you can repeat every day.

Ongoing, not a short course. The label's studies ran 26 weeks and then a second 26 weeks. In the second half, people switched to placebo had more belly fat on their scans again, so the results the label describes go with staying on it.

For planning, 26 weeks at 1.4 mg a day is 254.8 mg, and at 2 mg a day it is 364 mg. Compare vendors on price per milligram against a total like that, not on the price of one vial.

A mixed vial goes on a 28-day clock in the fridge the day water goes in, however much of it gets used. At a daily amount of 1 to 2 mg, a vial runs out well inside that window: a 10 mg vial lasts 7 days at 1.4 mg, 5 days at 2 mg and 10 days at 1 mg. A 20 mg vial, if a seller offers one, lasts 14 days at 1.4 mg, and a 5 mg vial lasts 3 days.

The approved kits work differently, so don't carry their numbers over. The Egrifta WR label has you keep a mixed vial at room temperature and throw it out 7 days after mixing, and the Egrifta SV label has you use the dose right after mixing and discard the rest. The 28-day fridge clock for research vials is the general figure for mixed peptides and bacteriostatic water, and no tesamorelin study tested it.

The pairing people describe is tesamorelin with ipamorelin, as two separate injections. No study tests the two together, and each has its own amounts on its own dosage chart. CJC-1295 comes up too, and it is also a growth hormone-releasing hormone analog, so it overlaps with tesamorelin more than it adds to it.

These are the effects the labels list, not findings from a study of research vials.

Swelling, joint aches or tingling in the hands. The label lists fluid retention, with swelling, joint pain and carpal tunnel symptoms, among the most common reactions.

Rising blood sugar. The label lists glucose intolerance and diabetes as warnings, and it says to monitor.

Redness or itching where you injected. The label lists injection site reactions, and it says to rotate spots around the belly.

The labels list active cancer, pregnancy, and a removed or damaged pituitary gland as reasons not to use it.